Biotinylated Anti-human CD16 Antibody (3G8, Human IgG1 Fc Silent Kappa)
$95.00 – $190.00
Recombinant anti-human CD16 monoclonal antibody (Clone 3G8, Biotinylated), engineered with a Human IgG1 Fc-Silent domain to minimize non-specific Fc receptor binding during cell surface analysis. Variable regions are derived from the classic mouse anti-human CD16 clone 3G8 and recombinantly expressed in mammalian cells.
- Form & Conjugation: Biotinylated, Flow Cytometry Grade
- Applications: Flow Cytometry (FC)
- Alternative Formats: Non-biotinylated FC grade, unconjugated in vivo grade, and alternative anti-human CD16 clones are also available.
- Details & Specifications
- References
| Catalog No. | PA007332.h1Fs-b |
|---|---|
| Product Name | Biotinylated Recombinant Anti-human CD16 Monoclonal Antibody (Clone: 3G8), Human IgG1 Fc Silent Kappa |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Clone | 3G8 |
| Isotype | Human IgG1 Fc Silent Kappa. |
| Source/Host | The site-directed biotinylated recombinant anti-human CD16 monoclonal antibody (clone: 3G8) was produced in mammalian cells. |
| Specificity/Sensitivity | The site-directed biotinylated recombinant 3G8 antibody specifically binds to human and non-human primate CD16. |
| Applications | Flow cytometry (FC) with various dye conjugation through streptavidin; conjugation to streptavidin agarose beads or streptavidin magnetic beads. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Conjugate | Biotin-conjugated. |
| Purity | >95% by SDS-PAGE under reducing conditions. |
| Shipping | The 3G8 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Recombinant mouse IgG1 isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
PA007332.h1Fs-b: Biotinylated Recombinant Anti-human CD16 Monoclonal Antibody (Clone: 3G8), Human IgG1 Fc Silent Kappa
Recombinant human IgG1 monoclonal antibody with site-directed biotinylation through the Avi tag at the C-terminus of the antibody heavy chain.
The recombinant 3G8 antibody binds to human and non-human primate CD16 or FcγRIII, a cluster of differentiation molecule found on the surface of natural killer cells, neutrophils, monocytes, macrophages, and certain T cells. CD16 consists of Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). The most well-researched membrane receptor implicated in triggering lysis by NK cells, CD16 is a molecule of the immunoglobulin superfamily (IgSF) involved in antibody-dependent cellular cytotoxicity (ADCC). It can be used to isolate populations of specific immune cells through fluorescent-activated cell sorting (FACS) or magnetic-activated cell sorting, using antibodies directed towards CD16.
References of Anti-Human CD16 Monoclonal Antibody (Clone: 3G8):
Kwon, et al. PLoS One. 2023 Jun 9;18(6):e0286915. PMID: 37294741
“Natural killer (NK) cells play an essential role in cancer immunotherapy, and their activation often relies on CD16-mediated signaling pathways. In this study, we systematically compared the downstream functional outcomes of using different anti-CD16 antibody clones, including 3G8, DJ130c, and KD1, on human peripheral blood NK cells. Our results show that clone 3G8 induced the most robust NK cell proliferation, degranulation, and inflammatory cytokine secretion compared to other candidate clones.”
Ochiel, et al. Front Immunol. 2024 Apr 9;15:1356391. PMID: 38711484
“Recombinant Factor VIII Fc fusion proteins (rFVIIIFc) are widely used therapeutic agents, yet the impact of the large FVIII moiety on Fc-mediated effector functions remains poorly understood. Here, we investigated how the steric presence of the FVIII moiety modulates Fc binding to FcγRIIIa (CD16) and subsequent natural killer (NK) cell activation. Using the CD16-blocking monoclonal antibody clone 3G8, we confirmed that rFVIIIFc interacts directly with CD16+ NK cells to trigger downstream intracellular signaling and effector cytokine release.”
Sachan, et al. PLoS Pathog. 2023 Sep 11;19(9):e1011617. PMID: 37695786
“Chronic lentivirus infections severely impair natural killer (NK) cell functionality, yet the precise intracellular signaling defects remain incompletely mapped. We utilized single-cell multiplexed signaling assays to profile downstream targets of the CD16 receptor during active viral infection. Our findings demonstrate that an IL-18 and ADAM17-dependent pathway drives the shedding of CD16, which was validated using clone 3G8 to track and block functional surface CD16 expression.”
Gomez-Milla, et al. Int J Mol Sci. 2024 Jul 12;25(14):7621. PMID: 39062864
“The low-affinity IgG receptor FcγRIIIa (CD16) displays genetic polymorphisms, particularly the F158V variation, which influences antibody binding affinity and clinical responses to therapeutic antibodies. To dissect these differences, we engineered NK-92 cell lines to express single or combined allelic variants of the FCGR3A gene. Functional characterization using the anti-CD16 monoclonal antibody clone 3G8 demonstrated distinct differences in receptor trigger thresholds and downstream killing dynamics between the high-affinity and low-affinity variants.”
5. Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
Georg, et al. Cell. 2022 Jan 20;185(2):292-312.e25. PMID: 34968393
“Severe COVID-19 is characterized by profound immune dysregulation, hyperinflammation, and progressive lung damage. We discovered that complement activation in severe patients drives ectopic upregulation of the low-affinity IgG receptor CD16 (FcγRIII) on T cells, rendering them highly cytotoxic. Blockade of this aberrant CD16 expression on T cells using the 3G8 monoclonal antibody significantly reduced immune-complex-mediated vascular injury, highlighting CD16 as a potential therapeutic target.”
For more technical references or data sheets regarding the Recombinant Anti-Human CD16 Monoclonal Antibody (Clone: 3G8) formats, please contact our scientific support team at message@sydlabs.com.
Syd Labs provides the following in vivo grade recombinant anti-human CD16, CD32, and CD64 monoclonal antibodies:
Recombinant Anti-human CD16 monoclonal antibody (Clone: 3G8)
Recombinant Anti-human CD32 monoclonal antibody (Clone: IV.3)
Recombinant Anti-human CD64 monoclonal antibody (Clone: H22)
Syd Labs provides the following in vivo grade recombinant anti-mouse CD16, CD32, and CD64 monoclonal antibodies:
Recombinant Anti-mouse CD16/CD32 monoclonal antibody (Clone: 2.4G2)
Syd Labs provides the following recombinant anti-human CD16, CD32, and CD64 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD16 monoclonal antibody (Clone: 3G8) for flow cytometry
Recombinant Anti-human CD32 monoclonal antibody (Clone: IV.3) for flow cytometry
Recombinant Anti-human CD64 monoclonal antibody (Clone: H22) for flow cytometry
Syd Labs provides the following recombinant anti-mouse CD16, CD32, and CD64 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD16/CD32 monoclonal antibody (Clone: 2.4G2) for flow cytometry
You may also like…
- Select optionsQuick View
- Select optionsQuick View
- Select optionsQuick View